Tarsus Pharmaceuticals, Inc. — Director's Dealing 2021

Mar 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-03-02

Reporting Person: Holdbrook Mark J. (V.P., Clinical Affairs)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-02	Stock Option (right to buy)	$34.72	A	14300	Acquired	2031-03-02	Common Stock (14300)	Direct

Footnotes

F1: Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan. 25% of the option shares shall vest and become exercisable on March 2, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years.